See-Chun Phan Selected Research

motexafin gadolinium

12/2009	Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.
11/2007	Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
8/2007	Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
3/2005	Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme.
1/2004	Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
7/2003	Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

See-Chun Phan Research Topics

Disease

8	Neoplasms (Cancer) 01/2017 - 07/2003
4	Brain Neoplasms (Brain Tumor) 11/2007 - 07/2003
3	Glioblastoma (Glioblastoma Multiforme) 01/2017 - 03/2005
3	Edema (Dropsy) 01/2017 - 11/2013
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2014 - 08/2007
2	Disease Progression 01/2017 - 01/2017
2	Fatigue 01/2017 - 08/2007
2	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 09/2013
2	Breast Neoplasms (Breast Cancer) 04/2011 - 09/2010
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2017
1	Hypoalbuminemia 01/2015
1	Carcinoma (Carcinomatosis) 09/2010
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2009
1	Lung Neoplasms (Lung Cancer) 08/2007
1	Agranulocytosis (Granulocytopenia) 08/2007
1	Nausea 08/2007
1	Dehydration (Water Stress) 08/2007
1	Vomiting 08/2007

Drug/Important Bio-Agent (IBA)

6	onartuzumabIBA 01/2017 - 09/2013
6	motexafin gadoliniumIBA 12/2009 - 07/2003
5	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2017 - 09/2013
4	Bevacizumab (Avastin)FDA Link 01/2017 - 04/2011
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 09/2014
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2014 - 11/2013
2	ErbB Receptors (EGF Receptor)IBA 11/2013 - 04/2011
1	LigandsIBA 01/2017
1	MethyltransferasesIBA 01/2017
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017
1	vinyltriethoxysilane (VTES)IBA 01/2015
1	Monoclonal AntibodiesIBA 01/2015
1	Proteins (Proteins, Gene)FDA Link 09/2014
1	Messenger RNA (mRNA)IBA 09/2014
1	AmphiregulinIBA 09/2014
1	EpiregulinIBA 09/2014
1	Biological ProductsIBA 09/2013
1	Hormones (Hormone)IBA 09/2010
1	Estrogens (Estrogen)FDA Link 09/2010
1	Progesterone Receptors (Progesterone Receptor)IBA 09/2010
1	Goserelin (Zoladex)FDA Link 09/2010
1	Anastrozole (Arimidex)FDA LinkGeneric 09/2010
1	Aromatase InhibitorsIBA 09/2010
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 09/2010
1	Dihydrotachysterol (AT 10)IBA 11/2007
1	Antineoplastic Agents (Antineoplastics)IBA 08/2007
1	Cisplatin (Platino)FDA LinkGeneric 08/2007
1	Docetaxel (Taxotere)FDA Link 08/2007
1	AntioxidantsIBA 08/2007

Therapy/Procedure

4	Radiotherapy 11/2007 - 07/2003
2	Therapeutics 01/2017 - 11/2007
1	Drug Therapy (Chemotherapy) 04/2011